Market Overview:
The global drugs for differentiated thyroid cancer market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of differentiated thyroid cancer, rising awareness about different treatment options available for differentiated thyroid cancer, and technological advancements in the field of oncology. The global drugs for differentiated thyroid cancer market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into radioiodine ablation, THS suppression therapy, chemotherapy, targeted multikinase therapy (TMK), and others. On the basis of application, the market is segmented into hospitals, oncology centers/clinics/hospitals pharmacies retail pharmacies).
Product Definition:
Differentiated thyroid cancer is a cancer that starts in the thyroid gland. The thyroid gland is located in the neck. Differentiated thyroid cancer is the most common type of thyroid cancer. Drugs for differentiated thyroid cancer are used to treat this type of cancer.
Radioiodine Ablation:
Radioiodine Ablation, also known as I-131 ablation is a minimally invasive technique that uses radioisotope to treat cancer. Radioiodine treatment is carried out in the thyroid gland and concentrates on the tumor cells. The procedure takes about 45 minutes and causes less damage to other tissues compared to surgical procedures.
Thyroid Stimulating Hormone (THS) Suppression:
Thyroid stimulating hormone (TSH) is a peptide hormone that regulates the release of thyroid hormones. TSH stimulates the release of thyroid hormones from the thyrotrophs in the glandular cells. The normal range for TSH is 0-4 mU/L, while an elevated level of more than 10 mU/L indicates hypothyroidism and below 10mU/L - hyperthyroidism respectively.
Application Insights:
The oncology canters segment dominated the global market in 2017. This is owing to factors such as an increase in the number of approvals for targeted therapy drugs and an increasing prevalence of cancer across various sites. For instance, according to WHO, around 1 in 6 deaths occur due to cancer worldwide. In 2018, around 2.09 million died due to this disease globally (1). Radioiodine ablation was the most popular drug used for differentiated thyroid cancer treatment among oncology canters in 2017 because it is a well-established method with wide application scope and low cost compared to other methods (2).
However, hospitals are expected To witness lucrative growth over the forecast period owing t o r e p u r s i o n c a n d f o r m u l t i k n a s e t h y r o d i d e - b l e m c R&D investment by companies.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; in this region. Moreover, an increase in prevalence of differentiated thyroid cancer is also one of the major factors responsible for its largest share. For instance, according to data published by American Cancer Society (ACS), it was estimated that around 18,000 new cases were diagnosed in U.S.
Growth Factors:
- Increasing incidence of differentiated thyroid cancer
- Growing awareness about differentiated thyroid cancer and its treatment options
- Rising demand for better and more effective treatments for differentiated thyroid cancer
- Availability of novel drugs and therapies for the treatment of differentiated thyroid cancer
- Growing number of clinical trials being conducted on drugs for the treatment of differentiated thyroid cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs for Differentiated Thyroid Cancer Market Research Report
By Type
Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Others
By Application
Hospitals, Oncology Canters, Hospital Pharmacies, Retail Pharmacies
By Companies
Mylan pharmaceuticals, Takeda, Alara Pharmaceutical, Abbott laboratories, Bristol Myers, Teva, Jerome Stevens, Mylan pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
181
Number of Tables & Figures
127
Customization Available
Yes, the report can be customized as per your need.
Global Drugs for Differentiated Thyroid Cancer Market Report Segments:
The global Drugs for Differentiated Thyroid Cancer market is segmented on the basis of:
Types
Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Oncology Canters, Hospital Pharmacies, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Mylan pharmaceuticals
- Takeda
- Alara Pharmaceutical
- Abbott laboratories
- Bristol Myers
- Teva
- Jerome Stevens
- Mylan pharmaceuticals
Highlights of The Drugs for Differentiated Thyroid Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Radioiodine Ablation
- Thyroid Stimulating Hormone (THS) Suppression
- Chemotherapy
- Targeted Multikinase Therapy
- Others
- By Application:
- Hospitals
- Oncology Canters
- Hospital Pharmacies
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs for Differentiated Thyroid Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one answer to this question as the best drugs for differentiating thyroid cancer will vary depending on the type of thyroid cancer, its location, and other factors. However, some common types of drugs used to differentiate thyroid cancer include radioactive iodine (RAI) therapy and surgery.
Some of the key players operating in the drugs for differentiated thyroid cancer market are Mylan pharmaceuticals, Takeda, Alara Pharmaceutical, Abbott laboratories, Bristol Myers, Teva, Jerome Stevens, Mylan pharmaceuticals.
The drugs for differentiated thyroid cancer market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Drugs for Differentiated Thyroid Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Drugs for Differentiated Thyroid Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Drugs for Differentiated Thyroid Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Drugs for Differentiated Thyroid Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Drugs for Differentiated Thyroid Cancer Market Size & Forecast, 2020-2028
4.5.1 Drugs for Differentiated Thyroid Cancer Market Size and Y-o-Y Growth
4.5.2 Drugs for Differentiated Thyroid Cancer Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Radioiodine Ablation
5.2.2 Thyroid Stimulating Hormone (THS) Suppression
5.2.3 Chemotherapy
5.2.4 Targeted Multikinase Therapy
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Oncology Canters
6.2.3 Hospital Pharmacies
6.2.4 Retail Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Drugs for Differentiated Thyroid Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Drugs for Differentiated Thyroid Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Radioiodine Ablation
9.6.2 Thyroid Stimulating Hormone (THS) Suppression
9.6.3 Chemotherapy
9.6.4 Targeted Multikinase Therapy
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Oncology Canters
9.10.3 Hospital Pharmacies
9.10.4 Retail Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Radioiodine Ablation
10.6.2 Thyroid Stimulating Hormone (THS) Suppression
10.6.3 Chemotherapy
10.6.4 Targeted Multikinase Therapy
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Oncology Canters
10.10.3 Hospital Pharmacies
10.10.4 Retail Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Radioiodine Ablation
11.6.2 Thyroid Stimulating Hormone (THS) Suppression
11.6.3 Chemotherapy
11.6.4 Targeted Multikinase Therapy
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Oncology Canters
11.10.3 Hospital Pharmacies
11.10.4 Retail Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Radioiodine Ablation
12.6.2 Thyroid Stimulating Hormone (THS) Suppression
12.6.3 Chemotherapy
12.6.4 Targeted Multikinase Therapy
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Oncology Canters
12.10.3 Hospital Pharmacies
12.10.4 Retail Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Radioiodine Ablation
13.6.2 Thyroid Stimulating Hormone (THS) Suppression
13.6.3 Chemotherapy
13.6.4 Targeted Multikinase Therapy
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Oncology Canters
13.10.3 Hospital Pharmacies
13.10.4 Retail Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Drugs for Differentiated Thyroid Cancer Market: Competitive Dashboard
14.2 Global Drugs for Differentiated Thyroid Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Mylan pharmaceuticals
14.3.2 Takeda
14.3.3 Alara Pharmaceutical
14.3.4 Abbott laboratories
14.3.5 Bristol Myers
14.3.6 Teva
14.3.7 Jerome Stevens
14.3.8 Mylan pharmaceuticals
